Innate Pharma logo
Innate Pharma
IPHA | NASDAQ
Chart Builder DCF Calculator
$1.41
+$0.03 (+2.17%)
At close: Nov 16, 2026, 4:00 PM ET
$1.44
+$0.03 (+2.12%)
After-hours: Nov 16, 2026, 4:19 PM ET

Innate Pharma Company Profile

Company profile explained

Company Profile

Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.

Key Executives

Name Position
Jonathan E. Dickinson Chief Executive Officer & Director
Frederic Lombard Senior Vice President & Chief Financial Officer
Yannis Morel Executive Vice President & Chief Operating Officer
Alessandro Moretta Founder
Claire de Saint Blanquat Vice President of Legal & Corporate Affairs and Secretary of the Supervisory Board
François Romagné Founder
Jean Jacques Fournié Founder
Marc Bonneville Founder
Odile Belzunce VP, Chief of Compliance & Operations Officer and Interim Head of HR
Sonia Quaratino Executive Vice President & Chief Medical Officer
Stephanie Cornen Vice President of Investor Relations, Communication & Commercial Strategy

Latest SEC Filings

Date Type Title
Oct 27, 2026 6-K Filing
Oct 21, 2026 6-K Filing
Oct 20, 2026 6-K Filing
Sep 17, 2026 6-K Filing
Sep 17, 2026 6-K Filing
Sep 17, 2026 6-K Filing
Sep 10, 2026 6-K Filing
Sep 02, 2026 6-K Filing
Aug 19, 2026 6-K Filing
Aug 14, 2026 6-K Filing
View All SEC Filings ➞
Innate Pharma
Innate Pharma logo
Country France
IPO Date Oct 17, 2019
Industry Biotechnology
Sector Healthcare
Employees 163
CEO Jonathan E. Dickinson

Contact Details

117, Avenue de Luminy Marseille, PAC 13009 France

Stock Details

Ticker Symbol IPHA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001598599
CUSIP Number 45781K204
ISIN Number US45781K2042
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.